Nordea Investment Management AB Has $2.21 Million Position in Ultragenyx Pharmaceutical Inc. $RARE

Nordea Investment Management AB grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 59.8% in the second quarter, HoldingsChannel.com reports. The fund owned 60,176 shares of the biopharmaceutical company’s stock after acquiring an additional 22,509 shares during the period. Nordea Investment Management AB’s holdings in Ultragenyx Pharmaceutical were worth $2,208,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. WCM Investment Management LLC grew its stake in Ultragenyx Pharmaceutical by 4.1% in the second quarter. WCM Investment Management LLC now owns 210,469 shares of the biopharmaceutical company’s stock valued at $7,686,000 after acquiring an additional 8,256 shares during the period. CWM LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 1,171.2% during the 2nd quarter. CWM LLC now owns 4,144 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 3,818 shares in the last quarter. Aberdeen Group plc grew its position in shares of Ultragenyx Pharmaceutical by 4.6% in the 2nd quarter. Aberdeen Group plc now owns 501,056 shares of the biopharmaceutical company’s stock valued at $18,218,000 after purchasing an additional 22,152 shares during the period. Vontobel Holding Ltd. acquired a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $380,000. Finally, KLP Kapitalforvaltning AS increased its position in shares of Ultragenyx Pharmaceutical by 8.6% during the second quarter. KLP Kapitalforvaltning AS now owns 17,700 shares of the biopharmaceutical company’s stock worth $644,000 after acquiring an additional 1,400 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Activity

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares in the company, valued at $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Howard Horn sold 7,942 shares of the stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $31.51, for a total value of $250,252.42. Following the transaction, the chief financial officer owned 98,227 shares in the company, valued at approximately $3,095,132.77. This trade represents a 7.48% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,456 shares of company stock worth $328,486. Insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Wedbush reduced their price objective on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a research report on Monday, July 14th. Canaccord Genuity Group reduced their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th. Wells Fargo & Company began coverage on shares of Ultragenyx Pharmaceutical in a report on Monday. They issued an “overweight” rating and a $65.00 price objective on the stock. Finally, Morgan Stanley reduced their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, July 14th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $82.27.

Ultragenyx Pharmaceutical Stock Down 3.1%

Shares of NASDAQ RARE opened at $33.14 on Thursday. The business’s 50 day moving average price is $30.55 and its two-hundred day moving average price is $32.91. The company has a market cap of $3.19 billion, a PE ratio of -5.99 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a twelve month low of $25.81 and a twelve month high of $56.38.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The company had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. During the same period in the previous year, the company posted ($1.52) EPS. The firm’s revenue for the quarter was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.